Category Archives: Events

Latest From
Events

BIO is seeking to bring the most innovative thinkers in biotechnology together at the BIO International Convention, June 23-26th, 2014, in San Diego, CA. Speaking at the BIO International Convention gives you access to biotech thought leaders from over 4,000 companies in 65 countries. BIO is seeking speakers who are forward leaning, engaging and who drive meaningful discussion about what’s on the forefront of the industry. Education enhancements in 2014 include: streamlined session tracks organized Read More >

NovelMed Therapeutics will be presenting at the upcoming BIO Investor Forum in October in San Francisco. Read below to learn more about their antibodies portfolio, what differentiates their company for the competition, and other interesting facts about the company. Company Snapshot What is your company’s lead product or technology? NovelMed has developed a portfolio of fully humanized monoclonal antibodies that selectively target only the disease-associated Complement System. As such, NovelMed’s antibodies are active against multiple Read More >

Earlier this week, we featured a presenting company for our upcoming BIO Investor Forum event in San Francisco in our ‘company snapshot‘ feature. For our next post, we spoke to MAX BioPharma, who will be giving a presentation in our Discovery Company presentation track, which features companies in their Seed or Series A financing rounds, with under 25 million raised to date. Read on to learn more about this Discovery Company. Company Snapshot What Read More >

The BIO Investor Forum will be taking place this October in San Francisco for its 12th annual event. So far this year, the hot topic is, of course, the hot market. Out of all the therapeutic US companies that have had an IPO in 2013, 71% of them have attended the BIO Investor Forum. The program for the event will thus feature two great panels about the recent IPO activity, in addition to other therapeutic workshops Read More >

As detailed in The New York Times, the potential for deal-making in the industry has resulted in a big surge in the biotech sector. According to the article, last month alone, seven companies completed I.P.O’s and at least five are lined up behind them. Furthermore, according to data provided by NASDAQ, all 16 of the biotechnology companies that have gone public this year are up 48 percent on average from their offering prices. In fact Read More >